Our global life sciences company brings diagnostic testing & drug development together. Explore what we do.
For all whole exome and whole genome sequencing tests performed at MNG, we offer a complete data reassessment. We re-evaluate all of the aligned sequencing data as if it has not yet been evaluated by re-classifying all sequencing variants using our MNG Genome Manager® analysis pipeline. The clinical reporting team reviews all variants to assess for any classification updates or newly relevant variants and re-examines copy number data. An updated proband report will be provided even if no changes are found.
All MNG Exome and MNGenome® reports are eligible for a no-cost, full data reassessment 6 months after the initial report date and once per 12 month period thereafter. Reassessments are available indefinitely, but are limited to the data generated when the original sequencing was performed.